Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

SLS

SELLAS Life Sciences (SLS)

SELLAS Life Sciences Group Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SLS
FechaHoraFuenteTítuloSímboloCompañía
11/03/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLSSELLAS Life Sciences Group Inc
25/01/202405:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLSSELLAS Life Sciences Group Inc
19/01/202415:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLSSELLAS Life Sciences Group Inc
05/01/202415:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLSSELLAS Life Sciences Group Inc
09/11/202315:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLSSELLAS Life Sciences Group Inc
21/06/202305:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLSSELLAS Life Sciences Group Inc
28/04/202315:23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SLSSELLAS Life Sciences Group Inc
28/04/202315:14Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SLSSELLAS Life Sciences Group Inc
16/03/202315:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SLSSELLAS Life Sciences Group Inc
24/02/202316:13Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:SLSSELLAS Life Sciences Group Inc
03/02/202316:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SLSSELLAS Life Sciences Group Inc
15/11/202212:05TipRanksSELLAS Life Sciences Group (SLS) Gets a Buy from Maxim GroupNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202210:21TipRanksSELLAS Craters After Postponing Cancer Drug MilestoneNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202207:15GlobeNewswire Inc.SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial ResultsNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202206:50GlobeNewswire Inc.SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid LeukemiaNASDAQ:SLSSELLAS Life Sciences Group Inc
14/11/202206:49Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SLSSELLAS Life Sciences Group Inc
11/11/202211:55TipRanksMaxim Group Reaffirms Their Buy Rating on SELLAS Life Sciences Group (SLS)NASDAQ:SLSSELLAS Life Sciences Group Inc
10/11/202207:30GlobeNewswire Inc.SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant AdvanceNASDAQ:SLSSELLAS Life Sciences Group Inc
03/11/202208:36GlobeNewswire Inc.SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual MeetingNASDAQ:SLSSELLAS Life Sciences Group Inc
02/11/202207:30GlobeNewswire Inc.SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022NASDAQ:SLSSELLAS Life Sciences Group Inc
17/10/202207:30GlobeNewswire Inc.SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022NASDAQ:SLSSELLAS Life Sciences Group Inc
11/10/202207:30GlobeNewswire Inc.SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-SNASDAQ:SLSSELLAS Life Sciences Group Inc
29/09/202207:15GlobeNewswire Inc.SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 FormulationsNASDAQ:SLSSELLAS Life Sciences Group Inc
22/09/202207:30GlobeNewswire Inc.SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual MeetingNASDAQ:SLSSELLAS Life Sciences Group Inc
14/09/202207:30GlobeNewswire Inc.SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28thNASDAQ:SLSSELLAS Life Sciences Group Inc
08/09/202207:00GlobeNewswire Inc.SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022NASDAQ:SLSSELLAS Life Sciences Group Inc
24/08/202207:30GlobeNewswire Inc.SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell LineNASDAQ:SLSSELLAS Life Sciences Group Inc
16/08/202215:08Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SLSSELLAS Life Sciences Group Inc
16/08/202207:30GlobeNewswire Inc.SELLAS Life Sciences’ Announces Election of Katherine Bach Kalin to its Board of DirectorsNASDAQ:SLSSELLAS Life Sciences Group Inc
11/08/202215:12GlobeNewswire Inc.SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial ResultsNASDAQ:SLSSELLAS Life Sciences Group Inc
 Showing the most relevant articles for your search:NASDAQ:SLS